Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

0
Player Avatar franktejon (< 20) Submitted: 7/6/2010 9:26:20 AM : Outperform Start Price: $4.85 GERN Score: -98.18

strong buy

Featured Broker Partners


Advertisement